Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
COVID-19
Barbara Campbell, NPR

Johnson & Johnson's COVID vaccine is effective against the delta variant, studies find

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

The Johnson & Johnson COVID-19 vaccine continued to be effective over the eight months it was studied in recipients, the company said.
The Johnson & Johnson COVID-19 vaccine was effective against the delta variant in a small study, the company announced Thursday.
David Zalubowski | AP

Johnson & Johnson's COVID-19 vaccine offers strong protection against the delta variant of the coronavirus, the company said Thursday. And the protection appears to last at least eight months.

The results follow similar announcements about the Pfizer and Moderna vaccines, in the fight against the fast-spreading delta strain.

In one small laboratory study, researchers observed what happened to the blood of eight vaccinated individuals when it was exposed to the delta variant. And they found that antibodies and immune system cells in the blood were highly effective at neutralizing the virus.

A second study involving 20 patients at Beth Israel Deaconess Medical Center in Boston showed similar results.

J&J also notes the vaccine continued to be effective over the eight months it has been studied in recipients. In fact, Dr. Mathai Mammen, the company's global head of research and development says the vaccine elicits a "strong neutralizing antibody response that does not wane; rather, we observe an improvement over time."

Both studies have been submitted but not yet been published in a peer-reviewed publication.

Copyright 2021 NPR. To see more, visit https://www.npr.org.